Shares of Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) were down 7.6% on Thursday . The company traded as low as $2.14 and last traded at $2.19, with a volume of 145,639 shares. The stock had previously closed at $2.37.

A number of equities analysts have recently issued reports on CNAT shares. FBR & Co restated a “buy” rating on shares of Conatus Pharmaceuticals in a research report on Monday, April 18th. Brean Capital restated a “buy” rating and set a $7.00 target price (down from $13.00) on shares of Conatus Pharmaceuticals in a research report on Monday, May 9th. Finally, Roth Capital started coverage on shares of Conatus Pharmaceuticals in a research report on Friday, July 1st. They set a “buy” rating on the stock. One analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $9.66.

The stock’s market cap is $45.52 million. The firm’s 50-day moving average price is $2.17 and its 200-day moving average price is $2.20.

Conatus Pharmaceuticals (NASDAQ:CNAT) last released its quarterly earnings results on Wednesday, August 3rd. The biotechnology company reported ($0.30) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.38) by $0.08. During the same period in the previous year, the firm posted ($0.31) earnings per share. Equities research analysts anticipate that Conatus Pharmaceuticals Inc. will post ($1.53) earnings per share for the current year.

An institutional investor recently raised its position in Conatus Pharmaceuticals stock. Jennison Associates raised its position in shares of Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) by 0.6% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 659,067 shares of the biotechnology company’s stock after buying an additional 3,983 shares during the period. Jennison Associates owned approximately 3.32% of Conatus Pharmaceuticals worth $2,933,000 at the end of the most recent quarter.

Conatus Pharmaceuticals Inc is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.